H. M. Mekki

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Nature Communications.

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Guizhen Wu, Zhixin Ma, Shi Chen, 2023, Signal Transduction and Targeted Therapy.

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial

Guizhen Wu, Jin Zhang, W. Lei, 2022, Signal Transduction and Targeted Therapy.

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

Z. Liu, Xin Zhang, K. Xu, 2022, medRxiv.